Projects

Preterm brain & cerebellar development

Bioinformatics and statistical analysis for the lab's research on how preterm birth, necrotizing enterocolitis (NEC), and SIDS affect the developing brain. Curates and quality-controls de-identified clinical datasets (EHR, imaging, laboratory, metabolomic, and transcriptomic data) for two preterm-infant studies, cerebellar development after preterm birth (176 infants) and NEC and brain injury (181 infants), and relates clinical exposures to brain development across more than 1,000 serial cranial ultrasound scans using linear, mixed-effects, segmented, logistic, and modified Poisson models. Builds reproducible RNA-seq pipelines for mouse and human cerebellar studies (differential expression, pathway, and GO enrichment). Quantifies rodent behavior with DeepLabCut and B-SOiD in a mouse model of prematurity insults (maternal immune activation and neonatal hypoxia) and its early-rehabilitation extension, and develops statistical and machine-learning models on Erasmus Ladder motor-coordination data from 160 preterm mice. Supports an astrocytoma immunotherapy project in another laboratory in the center with RNA-seq analysis. Figures, tables, sequencing-data repository submissions, and manuscript support for the resulting papers are part of the work.

Relocated from India to the United States. Completed an accelerated M.S. in Data Analytics (Western Governors University, 2024–2025) and the Imperial College London immunology course series (Coursera, 2023), and expanded into full-stack web development, Linux server administration, and cloud deployment, later used to build the open-source tools.

MyVivarium: open-source lab-animal platform

First-authored and built the full stack of MyVivarium, an open-source cloud app for managing animal colonies, developed under Digirobi Solutions in collaboration with the Sathyanesan Lab (Dr. Aaron Sathyanesan, University of Dayton). Published in 2025, it provides collaborative tracking, QR-code cage cards, task reminders, and a low-cost IoT system streaming temperature, humidity, light and activity in real time, deployable for roughly the cost of a website. Deployed at three partner labs (200+ animals). Version 2 (Docker, Playwright test suite) is in staged deployment at the University of Dayton (2026).

Neonatal brain-injury modeling

Contributed the mechanistic modeling to a collaborative neonatal-neuroscience study. Built a MATLAB SimBiology kinetic model of calcium/calmodulin–Src-kinase signaling in cortical neurons under hypoxia (piglet model) and ran a Sobol global sensitivity analysis on it, which identified a post-hypoxia window where modulating Src–NMDAR kinetics (PP2) limits calcium influx and pro-apoptotic signaling.

Cancer-nutrition databases & patent (consulting)

Founded Digirobi Solutions, an independent computational-biology and analytics consultancy, serving as the computational biologist on a client's cancer-nutrition project. Mined open and proprietary sources to build the cancer-genomics, drug, and nutrition databases behind the client's nutrigenomics tool, which links dietary compounds to cancer-relevant pathways, and co-invented the resulting granted US and European patents, whose rights were later acquired by another company. The consultancy also supported non-biomedical clients with marketing analytics and full web and server operations.

Multi-cell immuno-oncology biomarker modeling

Combined single-cell computational models into multi-cell “virtual tissue” predicting the chemokine, cytokine and cellular-biomarker profiles of inflamed tissue and the tumor microenvironment. Predictions matched co-culture measurements for 15 of 20 readouts after LPS stimulation and 16 of 20 after Pam3CSK4 stimulation, and the models were also personalized with multiple-myeloma cell-line genomics. Proposed as a high-throughput screen for anti-inflammatory and immuno-oncology therapeutics.

BEAT AML drug-response prediction & digital twins

Led the computational modeling (and second author) for the BEAT AML collaboration: built patient-specific digital twins from each genome and ran virtual drug tests; the predicted response to a BET inhibitor agreed with each patient's laboratory result for 93 of 100 AML patients. Built the data engine behind it: a 500+ cancer cell-line database with IC50 profiles (GDSC, CCLE, COSMIC, NCI-60) plus TCGA/cBioPortal. Also led a 10+ scientist team, setting model-validation standards.

Drug knowledge base & digital drug models

Built a ~200-compound drug knowledge base (targets, mechanism, pharmacokinetics, resistance) and turned each into a simulatable “digital drug” inside the disease models. Delivered 15+ internal training sessions, mentored junior scientists, and led the claim drafting and prosecution of the team's cancer-combination patent.

Mucosal & innate-immune modeling

Contributed the in-silico dendritic-cell modeling and analysis for antimicrobial-peptide collaborations, predicting, and validating with lab partners, how the defensin DEFB103 and histatin 5 tune inflammation up or down. These two papers account for 86 of the 158 Google Scholar citations (October 2026).

Drug-repurposing platform & predictive-modeling methods

Built the methodology that made high-throughput screening on the disease models scalable: a proprietary command language for scripting virtual experiments, executed across a Load Sharing Facility (LSF) compute grid that distributed simulations over networked machines and automatically collected, compared and scored the results. Ran high-throughput virtual drug-efficacy and repurposing screens on this platform. The approach was presented at ACR 2012 and is described in a published method patent application. The platform was adopted and further developed in-house.

Rheumatoid-arthritis model & repurposed combination therapy

Modeled 20+ interconnected signaling pathways across macrophages, T cells and other immune cell types, and led their integration into a rheumatoid-arthritis disease model that grew from four cell types to eight, validated against in-vivo data. Using high-throughput virtual screens, identified two synergistic repurposed-drug combinations, one of which reduced disease progression in a murine collagen-induced arthritis model. The compositions are described in two published patent applications.

Immune-signaling pathway modeling

First project: mechanistic ODE models of interleukin and TNF signaling in macrophages spanning 20+ interconnected pathways with perturbation-based validation, extended into an arachidonic-acid / EET model showing how a soluble epoxide hydrolase inhibitor calms NF-κB-driven inflammation. This early work helped shape the perturbation-and-validation approach later used across the company's computational-biology platform.